Hodgkin's lymphoma in adults: Diagnosis, treatment and followup;HodgkinLymphom beim erwachsenen patienten: Diagnostik, therapie und nachsorge

Deutsches Arzteblatt International

Volumn 110, Issue 11, 2013, Pages 177-183

  Rancea, Michaela ^a   Engert, Andreas ^b   Von Tresckow, Bastian ^b   Halbsguth, Teresa ^b   Behringer, Karolin ^b   Skoetz, Nicole ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; BRENTUXIMAB VEDOTIN; BUSULFAN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; MELPHALAN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL STUDY; COHORT ANALYSIS; FOLLOW UP; HISTOLOGY; HODGKIN DISEASE; HUMAN; INFECTION; INFERTILITY; INVOLVED FIELD RADIOTHERAPY; LEUKOPENIA; LYMPH NODE BIOPSY; LYMPHADENOPATHY; META ANALYSIS; METASTASIS; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; NEUROLOGIC DISEASE; OVERALL SURVIVAL; PATIENT DECISION MAKING; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; ADJUVANT RADIOTHERAPY; ADULT; EVIDENCE BASED MEDICINE; FEMALE; INTERNATIONAL COOPERATION; MALE; ONCOLOGY; PRACTICE GUIDELINE; PROCEDURES; STANDARDS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HODGKIN DISEASE; HUMANS; INTERNATIONALITY; MALE; MEDICAL ONCOLOGY; PRACTICE GUIDELINES AS TOPIC; RADIOTHERAPY, ADJUVANT;

EID: 84988306025     PISSN: 18660452     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2013.0177     Document Type: Article

References (33)

1. Diehl V, Thomas RK, Re D: Part II: Hodgkin's lymphoma-diagnosis and treatment. Lancet Oncol 2004; 5: 19-26
2. Engert A, Haverkamp H, Kobe C, et al.: Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): A random - ised, open-label, phase 3 non-inferiority trial. Lancet 2012; 379: 1791-9
3. Engert A, Plutschow A, Eich HT, et al.: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010; 363: 640-52
4. Engert A, Franklin J, Eich HT, et al.: Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007; 25: 3495-502
5. Noordijk EM, Carde P, Dupouy N, et al.: Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006; 24: 3128-35
6. Ferme C, Eghbali H, Meerwaldt JH, et al.: Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007; 357: 1916-27
7. von Tresckow B, Plutschow A, Fuchs M, et al.: Dose-Intensification in Early Unfavorable Hodgkin's Lymphoma: Final Analysis of the German Hodgkin Study Group HD14 Trial. J Clin Oncol 2012; 30: 907-13
8. Eich HT, Diehl V, Gorgen H, et al.: Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010; 28: 4199-206
9. Bauer K, Skoetz N, Monsef I, Engert A, Brillant C: Comparison of chemotherapy including escalated BEACOPP versus chemo - therapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 2011(8): CD007941
10. Engert A, Haverkamp H, Kobe C, et al.: Reduced intensity of chemotherapy and PET-giuded radiotherapy in patients with advanced stage Hodgkin lymphoma: An open-label, randomised phase 3 trial. Lancet 2012; 379: 1791-9
11. Kobe C, Dietlein M, Franklin J, et al.: Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood 2008; 112: 3989-94
12. Borchmann P, Haverkamp H, Diehl V, et al.: Eight Cycles of Escalated- Dose BEACOPP Compared With Four Cycles of Escalated- Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced- Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study Group. J Clin Oncol 2011; 29: 4234-42
13. IQWiG: Positronen-Emissions-Tomographie (PET) bei malignen Lymphomen: Institute for Quality + Efficiency in Health Care; 2009
14. Terasawa T, Nagai H: Current clinical evidence on interim fluo - rine-18 fluorodeoxy glucose positron emission tomography for advanced-stage Hodgkin lymphoma and diffuse large B-cell lymphoma to predict treatment outcomes. Leuk Lymphoma 2009; 50: 1750-2
15. Engert A, Ballova V, Haverkamp H, et al.: Hodgkin's lymphoma in elderly patients: A comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 2005; 23: 5052-60
16. Nogová L, Reineke T, Eich HT, et al.: Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lym - phoma: A retrospective analysis from the German Hodgkin Study Group (GHSG). Ann Oncol 2005; 16: 1683-7
17. von Tresckow B, Engert A: The role of autologous transplantation in Hodgkin lymphoma. Curr Hematol Malig Rep 2011; 6: 172-9
18. Schmitz N, Pfistner B, Sextro M, et al.: Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 2002; 359: 2065-71
19. Josting A, Rudolph C, Reiser M, et al.: Time-intensified dexa - methasone/cisplatin/cytarabine: An effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease. Ann Oncol 2002; 13: 1628-35
20. Linch DC, Winfield D, Goldstone AH, et al.: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-4
21. Morschhauser F, Brice P, Ferme C, et al.: Risk-adapted salvage treatment with single or tandem autologous stem-cell transplantation for first relapse/refractory Hodgkin's lymphoma: results of the prospective multicenter H96 trial by the GELA/SFGM study group. J Clin Oncol 2008; 26: 5980-7
22. Akpek G, Ambinder RF, Piantadosi S, et al.: Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 2001; 19: 4314-21
23. Smith SM, van Besien K, Carreras J, et al.: Second autologous stem cell transplantation for relapsed lymphoma after a prior autologous transplant. Biol Blood Marrow Transplant 2008; 14: 904-12
24. Ruffer JU, Ballova V, Glossmann J, et al.: BEACOPP and COPP/ ABVD as salvage treatment after primary extended field radia - tion therapy of early stage Hodgkins disease - results of the German Hodgkin Study Group. Leuk Lymphoma 2005; 46: 1561-7
25. Moskowitz AJ, Yahalom J, Kewalramani T, et al.: Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 2010; 116: 4934-7
26. Palmer J, Goggins T, Broadwater G, et al.: Early post transplant (F-18) 2-fluoro-2-deoxyglucose positron emission tomography does not predict outcome for patients undergoing auto-SCT in non-Hodgkin and Hodgkin lymphoma. Bone Marrow Transplant 2011; 46: 847-51
27. Courneya KS, Sellar CM, Stevinson C, et al.: Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. J Clin Oncol 2009; 27: 4605-12
28. Muller A, Keller K, Wacker J, et al.: Retransplantation of cryopreserved ovarian tissue: the first live birth in Germany. Dtsch Arztebl Int 2012; 109(1-2): 8-13
29. von Wolff M, Dian D: Fertility preservation in women with malignant tumors and gonadotoxic treatments. Dtsch Arztebl Int 2012; 109(12): 220-6
30. Hsiao W, Stahl PJ, Osterberg EC, et al.: Successful treatment of postchemotherapy azoospermia with microsurgical testicular sperm extraction: the Weill Cornell experience. J Clin Oncol 2011; 29: 1607-11
31. Dryver ET, Jernstrom H, Tompkins K, Buckstein R, Imrie KR Follow-up of patients with Hodgkin's disease following curative treatment: the routine CT scan is of little value. Br J Cancer 2003; 89: 482-6
32. Ng AK, Li S, Neuberg D, et al.: A prospective study of pulmonary function in Hodgkin's lymphoma patients. Ann Oncol 2008; 19 : 1754-8
33. Hodgson DC, Koh ES, Tran TH, et al.: Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 2007; 110: 2576-86.